2025
•Laura Spurgeon, MD, MPhil, Guy Betts, MD, and Robert Metcalf, MD, PhD; The Christie NHS Foundational Trust; “Multicenter Validation of P63 Immunohistochemistry (IHC) as a Prognostic Marker for Adenoid Cystic Carcinoma (Christie NHS)”
•Renata Ferrarotto, MD; MD Anderson Cancer Center; “Multicenter Validation of P63 Immunohistochemistry (IHC) as a Prognostic Marker for Adenoid Cystic Carcinoma (MDA)”
•J.Jack Lee, PhD, MS, DDS; MD Anderson Cancer Center; “Multicenter Validation of P63 Immunohistochemistry (IHC) as a Prognostic Marker for Adenoid Cystic Carcinoma (MDA)”
•John Ngo, PhD; Boston University; “Protease-activated antibodies for tumor-selective NOTCH-1 inhibition”

2024
•John Iafrate, MD, PhD; Massachusetts General Hospital; “The ACC Tumor Immune Microenvironment: Reversing HLA/B2M Downregulation to Support Immunotherapy Efficacy”
•Rajdeep Chakraborty, PhD; Macquarie University; “A Prelude towards transforming adenoid cystic carcinoma into an immune hot tumour”
•Bhumsuk Keam, MD; Seoul National University Hospital; “Multicenter Validation of P63 Immunohistochemistry (IHC) as a Prognostic Marker for Adenoid Cystic Carcinoma (SNUH)”
•Mridula George, MD; Rutgers Cancer Institute; “Patterns of care in the management of patients with Adenoid Cystic Carcinoma of the Breast”
•Stephen Doggett, MD and Drew Moghanaki, MD; Mission Viejo Hospital and UCLA; “CT-Guided LDR Brachytherapy for Adenoid Cystic Carcinoma Lung Metastases:  Efficacy and Safety Outcomes Followup”
•Liron Bar-Peled, PhD; Massachusetts General Hospital Cancer Center; “Chemical proteomics to target MYB in ACC”
•Miguel Rito, MD and Isabel Fonseca, MD, PhD; Instituto Português de Oncologia de Lisboa; “Multicenter Validation of P63 Immunohistochemistry (IHC) as a Prognostic Marker for Adenoid Cystic Carcinoma (Lisboa)”
•Francois-Regis Ferrand, MD; Gustave Roussy Institute; “Pathological review of ACC in the framework of a multiomic study (REFCORomics- PRTK2024/SPELCASTER-TRANSCAN3)”
•Carla van Herpen, Prof. MD, PhD; Radboud University Medical Center; “Multicenter Validation of P63 Immunohistochemistry (IHC) as a Prognostic Marker for Adenoid Cystic Carcinoma (Radboud)”
•Tony Amelio, PhD; H. Lee Moffitt Cancer Center & Research Institute, Inc.; “Molecular Characterization of the Salivary Adenoid Cystic Carcinoma Tumor Immune Landscape by Anatomic Subsite”
•Max Wintermark, MD; MD Anderson Cancer Center; “VEGFR inhibitors in ACC”
•Rajan Gogna, PhD; Virginia Commonwealth University School of Medicine; “To Study the Expression of Flower-Win and Flower-Lose in Adenoid Cystic Carcinoma (ACC)”
•Stephen Doggett, MD and Drew Moghanaki, MD; Mission Viejo Hospital and UCLA; “CT-Guided LDR Brachytherapy for Adenoid Cystic Carcinoma Lung Metastases:  Efficacy and Safety Outcomes”
•Damian Rieke, MD; Charite Comprehensive Cancer Center; “Identifying novel treatment options as well as predictive biomarkers for existing immune therapies in advanced ACC”

2023

•Xiaohong Chen, MD; Beijing Tongren Hospital; “JAG1 inhibitor combined with anti-PD-1 for adenoid cystic carcinoma”
•Erich Sturgis, MD, MPH, and Ray Wang, MD; Baylor College of Medicine; “Adenoid cystic carcinoma arising at non-salivary sites in the U.S.- A proposal for analysis of two national cancer datasets”
• Lin Zhang, MD; University of Pennsylvania; “Enhancing immuno-oncology strategies for Adenoid Cystic Carcinoma through precise targeting of cell surface proteins”
• Jacob Berchuk, MD, and Glenn Hanna, MD; Dana-Farber Cancer Institute; “Tissue-informed cell-free DNA Methylation analysis to detect Adenoid Cystic Carcinoma”
• Paolo Bossi, MD; University of Brescia; “In-depth analysis of salivary gland cancers from cell lines and genomic evaluation towards clinical trials in locally advanced and recurrent/metastatic disease – INDAGA trial-“
• Claudia Malheiros Coutinho Camillo, PhD; AC Camargo Cancer Center; “Adenoid cystic carcinoma models for determination of chemoresistance”
• Renata Ferarotto, MD; MD Anderson Cancer Center; “The Role of Pulmonary Metastasis Directed Therapy in Adenoid Cystic Carcinoma”
• Carlos Rodriguez-Russo, MD and Richard Bakst, MD; Icahn School of Medicine at Mount Sinai; “Assessing the Neural Tumor Microenvironment of Adenoid Cystic  Carcinoma”

2022

• Carla van Herpen, MD, PhD; Radboud University; “Exploration of the immune micro-environment of adenoid cystic carcinoma using multiplex immunohistochemistry”
• Maxim Pimkin, MD, PhD, and Stuart Orkin, MD; Dana-Farber Cancer Institute; “Direct gene-regulatory functions of MYB/MYBL1 fusion oncoproteins”
• Guopei Zhu, MD, PhD; Shanghai Jiao Ton University School of Medicine; “ACC patient-derived organoids”
• Oliver Jonas, PhD, and Glenn Hanna, MD; Dana-Farber Cancer Institute; “Therapeutic drug screening using a novel implantable microdevice (IMD) in adenoid cystic carcinoma (ACC): a window of opportunity study”
• Shannon MacDonald, MD, and Myrsini Ioannidou, MD; Mass General Hospital; “MGH ACC clinical database”
• Ana Kiess, MD, PhD; Johns Hopkins University; “A Phase 2, single-Arm, multi-center study of 177Lu-PSMA (177Lu-PNT2002) in patients with PSMA-positive ACC”
• Maxim Pimkin, MD, PhD, and Stuart Orkin, MD; Dana-Farber Cancer Institute; “Targeted protein degradation approaches to define the molecular mechanisms of MYB oncoproteins in ACC”
• Lin Zhang, MD, and Zhongyi Hu, PhD; University of Pennsylvania; “Computational prediction of immunotherapy targets for treatment of adenoid cystic carcinoma”

• Carla van Herpen, MD, PhD; Radboud University; “PSMA radioligand therapy for salivary gland cancer”
• Jon Schoenfeld, MD, MPhil, MPH; Dana-Farber Cancer Institute; “Stereotactic body radiotherapy (SBRT) for early treatment of oligometastatic ACC”
• Kathryn Brayer, PhD, and Scott Ness, PhD; University of New Mexico; “ACC bioinformatics project”
• Renata Ferrarotto, MD; MD Anderson; “Imaging features and natural history of metastatic ACC”
• Glenn Hanna, MD, and Keith Ligon, MD, PhD; Dana-Farber Cancer Institute; “Evaluating combination targeted therapy for patients with VEGFR-refractory advanced ACC using ex vivo patient derived cell lines (PDCL)”
• Lynn Bingle, PhD; University of Sheffield; “Defining the MYB-NFIB/MYB interactome in salivary and breast cells”
• Ali Khurram, BDS, PhD; University of Sheffield; “RadioPathomic analysis of ACC using artificial intelligence”
• Alberto Hernando Calvo, MD, and Aaron Hansen, MD; Princess Margaret Cancer Centre; “Dynamic evaluation of liquid biopsies in patients with recurrent or metastatic (R/M) salivary gland tumor (SGT) histologies (DELISH)”
• Renata Ferrarotto, MD; MD Anderson; “AL101 prior to standard-of-care surgery in patients with Notch activated adenoid cystic carcinoma”

• Vinod Saladi, PhD; Massachusetts Eye and Ear Institute; “Role of YAP/TEAD and p63 network in ACC”
• Liza Makowski, PhD, and Neil Hayes, MD, MS, MPH; University of Tennessee HSC; “Targeting T cell response in ACC”
• Renata Ferrarotto, MD; MD Anderson Cancer Center; “ACC microenvironment and spatial analysis using imaging mass cytometry”
• Xiaohong Chen, MD; Beijing Tongren Hospital; “Establishment of xenotransplantation model system for ACC”
• Yoshitsugu Mitani, DDS, PhD; MD Anderson Cancer Center; “Development of circulating extracellular vesicles as an early biomarker in patients with ACC”
• Scott Ness, PhD; University of New Mexico; “Biomarkers for ACC outcomes”
• Evgeny Izumchenko, PhD; University of Chicago; “Organoid development and integrated genomic characterization of ACC”
• Paul Swiecicki, MD, PhD; University of Michigan; “Characterization of novel tissue biomarkers in ACC”
• Mariana Brait, MSc, PhD; Johns Hopkins University; “Molecular validation of an in vivo model for ACC”
• Jose Javier Bravo-Cordero, PhD; Icahn School of Medicine at Mount Sinai; “Modeling metastatic dissemination of ACC in vivo”
• Daniel Pelaez, PhD; University of Miami; “Molecular surveillance of ACC”

• Jesse Boehm, PhD; Broad Institute; “ACC cancer dependency map”
• Mariana Brait, MSc, PhD; John Hopkins University; and Jose Javier Bravo-Cordero, PhD; Icahn School of Medicine at Mount Sinai; “ACC in vivo model system”
• Stephen Doggett, MD; Mission Viejo Hospital; “Brachytherapy in ACC”
• Leonard Zon, MD; Boston Children’s Hospital; “ATRA in ACC” (co-funding with the V-Foundation)
• Bertrand Baujat, MD, PhD; Sorbonne University; “REFCOR database analysis: ACC”
• Julia Thierauf, MD; Massachusetts General Hospital/Massachusetts Eye and Ear Institute; “FNA in ACC clinical management”
• Adam Fisch, MD, PhD; Massachusetts General Hospital/Massachusetts Eye and Ear Institute; “MYB and MYBL1 IHC in ACC”
• Bita Esmaeli, MD, FACS; MD Anderson Cancer Center; “Lacrimal ACC characterization”
• Jon Aster, MD, PhD; Brigham and Women’s Hospital; “BCL2 in ACC”
• Tatiana Karpinets, PhD and Andrew Futreal, PhD; MD Anderson Cancer Center; “Immune microenvironment and microbiome in ACC”
• Alexander Pearson, MD, PhD; University of Chicago; “Deep neural network development in ACC”

• Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “ACC Cell Line Banking”
• Jon Schoenfeld, MD, MPhil, MPH; Dana-Farber Cancer Institute; “Correlative studies for phase II of Pembrolizumab +/- RT in ACC”
• Rogerio Castilho, DDS, MS, PhD; University of Michigan; “HDAC inhibitors plus Cisplatin: mechanisms of action in ACC PDX”
• Simon Andreasen, MD, PhD; University of Copenhagen; and Britta Weigelt, PhD; Memorial Sloan Kettering Cancer Center; “Liquid biopsy in ACC”
• Robert Ramsay, PhD; University of Melbourne; “MYB cDNA vaccine in ACC”
• Angela Koehler, PhD; MIT/Koch Institute; “Advancing chemical probes in ACC”
• Scott Ness, PhD; University of New Mexico; and Simon Andreasen, MD, PhD; University of Copenhagen; “Defining ACC subgroups”
• Piero Dalerba, MD; Columbia University; “Pharmacological manipulation of cell differentiation in ACC”

• Carla van Herpen, MD, PhD; Radboud University; “Radiolabeled PSMA imaging in ACC”
• Robert Ramsay, PhD; University of Melbourne; “MYB cDNA vaccine in ACC”
• Jon Aster, MD, PhD; Brigham and Women’s Hospital; “NOTCH signature in ACC”

• Jens Lohr, MD, PhD; Dana Farber Cancer Institute; “Liquid Biomarkers in ACC”
• Nishant Agrawal, MD and Tanguy Seiwart, MD; The University of Chicago Medicine; “Clinical trial correlative studies: PD-1 inhibitor plus chemotherapy”
• Piero Dalerba, MD; Columbia University; “Tumor heterogeneity in ACC”
• Angela Koehler, PhD; Massachusetts Institute of Technology; “Targeting transcription factors in ACC”
• Bhumsuk Keam, PhD; Seoul National University; “Clinical trial correlative studies: axitinib”
• Renata Ferrarotto MD; MD Anderson Cancer Center; “ASCO Career Development Award cofunding: NOTCH-related studies”
• Robert Metcalf MD, PhD; University of Manchester; “Liquid biomarkers in ACC”
• Binbin Li, PhD; Peking University; “ACC Biomarkers and Diagnostics”
• Karl-Heinz Klempnauer, PhD; University of Munster; “Distinguished Researcher Award: MYB”
• Carlos Caulin, PhD; MD Anderson Cancer Center; “Transgenic mouse model for ACC”
• Nikolaus Schultz, PhD; Memorial Sloan Kettering Cancer Center; “ACC Genomic Datasets”
• Anna Keiss, MD, PhD; John Hopkins University; “Targeted Radiopharmaceutical Therapy for ACC”
• Derrick Lin, MD; Massachusetts Eye and Ear Institute/Massachusetts General Hospital; “ACC Tumor Biorepository and Registry”
• Scott Ness, PhD; University of New Mexico; “Screening assay development for ACC”
• Mariana Brait, MSc, PhD; John Hopkins University; “ACC Diagnostics”
• Robert Ramsay, PhD; University of Melbourne; “MYB cDNA vaccine”

• Arturo Sala, PhD; Brunel University; “Transgenic mouse model for ACC”
• Seema Agarwal, PhD; Georgetown University; “In vivo model for ACC”
• Mary Reyland, PhD and Antonio Jimeno, MD; University of Colorado; “Development of advanced ACC models”
• Silvio Gutkind, PhD; University of California San Diego; and Lars Engelhorn, PhD, University of Copenhagen; “Modeling ACC progression and targeted therapies”
• Jon Aster, MD, PhD; Brigham and Women’s Hospital; “NOTCH1 sequencing in ACC”
• Bradley Bernstein, MD, PhD; Massachusetts General Hospital; “Targeting MYB and epigenetic factors in ACC”
• Len Zon, MD; Harvard Stem Cell Institute/Boston’s Children Hospital; “Screening for MYB inhibitors in zebrafish”

• Arturo Sala, PhD; Brunel University; “Generating the MYB-NFIB fusion in vitro”
• Jon Aster, MD, PhD; Brigham and Women’s Hospital; “Biomarkers in ACC”
• Sergey Ivanov, PhD; Yale University; “Targeting cancer stem cells in ACC”
• Arturo Sala, PhD; Brunel University; “Assessing MYB-NFIB oncogenic potential in vitro”
• Joan Robbins, PhD; Tocagen; “Biomarkers of ACC infectability”
• Britta Weigelt, PhD, and Jorge Reis-FIlho, MD, PhD; Memorial Sloan Kettering Cancer Center; “Characterization of MYB-NFIB in ACC of the breast”
• Marc Pusztaszeri, MD; Geneva University Hospital; and William Faquin, MD, PhD; Massachusetts Eye and Ear Infirmary; “ACC Diagnostics”
• Karl-Heinz Klempnauer, PhD; University of Munster; “Development and screening assays for MYB inhibitors”
• Jon Aster, MD, PhD; Brigham and Women’s Hospital; “ACC Diagnostics”
• Rogerio Castilho, DDS, MS, PhD; University of Michigan; “Targeting ACC initiating cells”
• Adi Gazdar, MD; University of Texas Southwestern; “ACC cell lines”
• Frederic Kaye, MD; University of Florida; “ACC cell lines”
• Jon Schoenfeld, MD, MPhil, MPH; Dana Farber Cancer Institute; “Immunological markers in ACC”
• Seema Agarwal, PhD; Georgetown University; “ACC model systems”
• Christopher Moskaluk, MD, PhD; University of Virginia; “MYB co-factors in ACC”

• Robert Ramsay, PhD; University of Melbourne; and Goran Stenman, DMD, PhD; University of Gothenburg; “MYB-NFIB fusion mechanism of action in ACC”
• Patrick Ha, MD and Nishant Agarwal, MD; John Hopkins University, “ACC sequencing study”
• John Bushweller, PhD; University of Virginia; “Screening for MYB inhibitors”
• Richard Bakst, MD; Mount Sinai; “Perineural spread in ACC”
• Joan Robbins, PhD; Tocagen; “ACC infectability studies”
• Tan Ince, MD, PhD; University of Miami; “ACC cell lines”
• Michael Barrett, PhD; TGen; “Clinical trial correlative studies: vorinostat”
• Timothy Chan, MD, PhD, Luc Morris, MD, Allen Ho, MD, and Alan Ho, MD, PhD; Memorial Sloan Kettering Cancer Center; “ACC sequencing study”
• Kwok Wong, MD, PhD; Dana Farber Cancer Institute; “MYB-NFIB genetically engineered mouse model”
• Marc Pusztaszeri, MD; Geneva University Hospital; and William Faquin, MD, PhD; Massachusetts Eye and Ear Infirmary; “ACC Diagnostics”

• Scott Ness, PhD; University of New Mexico; “MYB Conference”
• Tom Gonda, PhD; University of Queensland; “In vivo models in ACC”
• Goran Stenman, DMD, PhD; University of Gothenburg; “1p deletions and receptor tyrosine kinases in ACC”
• Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking, Model Development and Genomics”

• Margaret Brandwein-Gensler, MD; University of Alabama, Birmingham; “HPV and ACC”
• Kwok Wong, MD, PhD; Dana Farber Cancer Institute; “MYB-NFIB genetically engineered mouse model”
• Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking, Model Development and Genomics”
• Wendell Yarbrough, MD, MMHC; Yale University; “TRKC and neurotrophic signaling in ACC”
• Scott Ness, PhD; University of New Mexico; “c-MYB variant activity in ACC”
• Bradley Bernstein, MD, PhD; Massachusetts General Hospital; “Role of MYB translocation on chromatin landscape in ACC”
• Len Zon, MD; Harvard Stem Cell Institute/Boston’s Children Hospital; “Screening for MYB inhibitors in zebrafish”
• Lurdes Queimado, MD, PhD; University of Oklahoma; “ACC cell lines”
• Jaques Nor, DDS, MS, PhD; University of Michigan; “Stem cells in ACC”

• Patrick Ha, MD; John Hopkins University, “Tumor suppressor screen In ACC PDXs”
• Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Genomic analysis in ACC”
• Timothy Bender, MS, PhD; University of Virginia; “MYB-NFIB fusion proteins in ACC”
• Tan Ince, MD, PhD; University of Miami; “ACC cell lines”
• Pat LoRusso, DO; Karmanos; “Clinical trial correlative studies: vorinostat”
• Christopher Moskaluk, MD, PhD; University of Virginia; “ACC disease pathway analysis”
• Andrew Futreal, PhD; Wellcome Trust Sanger Institute; “ACC genomics”
• Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “MYB-NFIB fusion gene and screening of ACC”

• Goran Stenman, DMD, PhD; University of Gothenburg; “Novel fusions in ACC”
• Jason Papin, PhD; University of Virginia; “Bioinformatics systems biology approach to ACC”
• Andrew Futreal, PhD; Sanger Institute; “ACC rearrangements”

• Mike Rothenburg, MD; Massachusetts General Hospital; “Model development and characterization”
• National Institute of Dental and Craniofacial Research; “Salivary Gland Tumor Research: Biorepository and RDCRN”
• Mary Pat Moyer, PhD; INCELL; “ACC cell lines”
• Patrick Ha, MD; John Hopkins University, “ACC cell lines from PDXs”
• John Basile, DDS, DMSc; University of Maryland; “Perineural invasion in ACC”
• Claudia Kirsch, MD; University of California, Los Angeles; “3T MRIs and radiologic differentiation in ACC”
• Naishuo Zhu, MD, PhD; Fudan University; “Metastasis-related gene function in ACC”
• Ed Harlow, PhD; Harvard University; “Genomic screens in ACC”

• National Disease Research Interchange; “Rare Disease Biospecimen Alliance”
• Andrew Futreal, PhD; Sanger Institute; “ACC sequencing pilot”
• Adel El-Naggar, MD, PhD; MD Anderson Cancer Center; “Biobanking and model development”

• Goran Stenman, DMD, PhD; University of Gothenburg; “Genomic imbalances in ACC”

• Christopher Moskaluk, MD, PhD; University of Virginia; “Biobanking and model development”